ImVisioN Therapeutics Inc. is a biotechnology company that is pioneering the use of intralymphatic immunotherapy (ILIT ™) to develop safe, effective and convenient treatments for major allergies. ImVisioN’s lead product, IVN201, is a MAT ™ immunotherapeutic that targets cat dander allergy, a common allergy inadequately addressed by available therapeutic interventions. ImVisioN also has programes to target birch pollen and house dust mite allergies, two of the most common allergies in man